A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
1期
已完成
NCT06023095
| 适应症 | Overweight, Obesity |
|---|
| 分期 | 1期 |
|---|
| 申办方 | Eli Lilly and Company |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 24 人 |
|---|
| 干预（药物） | LY3502970 |
|---|
| 开始日期 | 2023年9月21日 |
|---|
| 完成日期 | 2024年7月29日 |
|---|
| 结果公布日 | 2026年7月17日 |
|---|
摘要
The main purpose of this study is to learn about the safety and tolerability of LY3502970 when given to Chinese participants with obesity or overweight with weight-related comorbidities. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive LY3502970, or placebo given orally. For each participant, the study will last about approximately 22- and 30-weeks for both cohort 1 and 2, respectively including screening period.
Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Baseline through Week 18 (Cohort 1) & Week 26 (Cohort 2) · Participants
| LY3502970 (Cohort 1) | 10 Participants |
|---|
| LY3502970 (Cohort 2) | 8 Participants |
|---|
| Placebo | 3 Participants |
|---|
| LY3502970 (Cohort 1) | 0 Participants |
|---|
| LY3502970 (Cohort 2) | 0 Participants |
|---|
| Placebo | 0 Participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。